Reversal of visceral hypersensitivity in rat by Menthacarin®, a proprietary combination of essential oils from peppermint and caraway, coincides with mycobiome modulation
| Jazyk: | angličtina |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Unclassified drug Visceral sensitivity Assay Digestive function Treatment response DNA 18S Motor activity Essential oil Species composition Candida albicans High throughput sequencing Decanoic acid Antifungal activity Radial diffusion assay Fluconazole Priority journal Visceral hypersensitivity Intestine flora Antibiotic agent Mentha piperita Digestive tract agent Penicillin derivative Streptomycin Caraway Female Antifungal agent Drug mechanism Bacillus subtilis Physical sensitivity Drug megadose Abdominal pain DNA 16S Colorectal distension Digestive system disease Low drug dose IBS Octanoic acid Dose response Hypersensitivity Animal model Drug dose comparison Animal experiment Biology Peppermint oil Caraway oil Menthacarin Bacteria Fungi In vitro study Bacterial DNA Maternal deprivation Nonhuman Drug efficacy Viscera Fungal DNA Growth inhibition Dysbiosis Rat Microbiome Antibacterial activity Colorectal disease Controlled study Internal transcribed spacer 1 Mycobiome |
| Popis: | Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder associated with altered gastrointestinal microflora and increased nociception to colonic distension. This visceral hypersensitivity can be reversed in our rat maternal separation model by fungicides. Menthacarin® is a proprietary combination of essential oils from Mentha x piperita L. and Carum carvi. Because these oils exhibit antifungal and antibacterial properties, we investigated whether Menthacarin® can reverse existing visceral hypersensitivity in maternally separated rats. Methods: In non-handled and maternally separated rats, we used the visceromotor responses to colorectal distension as measure for visceral sensitivity. We evaluated this response before and 24 hours after water-avoidance stress and after 7 days treatment with Menthacarin® or control. The pre- and post-treatment mycobiome and microbiome were characterized by sequencing of fungal internal transcribed spacer 1 (ITS-1) and bacterial 16s rDNA regions. In vitro antifungal and antimicrobial properties of Menthacarin® were studied with radial diffusion assay. Key Results: Menthacarin® inhibited in vitro growth of yeast and bacteria. Water-avoidance caused visceral hypersensitivity in maternally separated rats, and this was reversed by treatment. Multivariate analyses of ITS-1 and 16S high throughput data showed that maternal separation, induced changes in the myco- and microbiome. Menthacarin® treatment of non-handled and maternally separated rats shifted the mycobiomes to more similar compositions. Conclusions & Inferences: The development of visceral hypersensitivity in maternally separated rats and the Menthacarin®-mediated reversal of hypersensitivity is associated with changes in the mycobiome. Therefore, Menthacarin® may be a safe and effective treatment option that should be tested for IBS. © 2018 The Authors. Neurogastroenterology & Motility Published by John Wiley & Sons Ltd. Chemicals / CAS: decanoic acid, 334-48-5, 3398-75-2; fluconazole, 86386-73-4; octanoic acid, 124-07-2, 1984-06-1, 74-81-7; peppermint oil, 8006-90-4; streptomycin, 57-92-1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|